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ABSTRACT
Introduction: With the introduction of positron-emitting radionuclides with half-lifes in days, such as
89Zr and 124I, radioimmunoscintigraphy (RIS) with positron-emitter-labeled monoclonal antibodies
(moAbs) becomes feasible. RIS, using positron emission tomography (immuno-PET), combines the spe-
cific localization of an antibody with the high resolution of a PET camera. In the present study, scinti-
graphic tumor imaging using chimeric moAb G250 labeled with 89Zr (immuno-PET) or 111In (RIS), and
[18F]FDG-(PET) was explored in rats with s.c. renal cell carcinoma (RCC) tumors.
Methods: Nude rats (6–8 rats per group) with s.c. SK-RC-52 tumors were i.v. injected with 4 MBq 111In-
DTPA-cG250, 20 MBq 89Zr-Df-cG250 or 4 MBq [18F]FDG. Planar 111In-DTPA-cG250 images were ob-
tained 5 minutes, and 24, 48, and 72 hours postinjection (p.i.). 3D PET imaging was performed 5 min-
utes, and 24, 48, and 72 hours after a 89Zr-Df-cG250 injection and 1 hour after a [18F]FDG injection
using a Siemens ECAT EXACT PET camera. Rats were killed after the last imaging session, and the up-
take of the radiolabel in the dissected tissues was determined.
Results: Both radiolabeled antibody preparations were stable during 4 days of incubation in serum at
37°C, and the immunoreactivity was preserved. Two (2) days after injection, s.c. tumors (100 mg) were
clearly visualized, both with 89Zr-Df-cG250 and 111In-DTPA-cG250. Tumors were not visualized with
[18F]FDG (uptake in tumor of 0.56 0.1 %ID/g, 1 hour p.i.). The biodistribution experiments showed an
identical uptake in the tumor for both 89Zr-Df-cG250 and 111In-DTPA-cG250 at 3 days p.i. (5.0 6 2.4
and 4.96 2.9 %ID/g, respectively). Blood levels at 3 days p.i. were also identical (1.4 6 0.4 versus 1.76
0.7 %ID/g), and no significant differences were found in the biodistribution of normal tissues between the
two radiolabeled cG250 preparations.
Conclusion: The cG250 antibody can be stably labeled with the positron-emitter 89Zr, while preserving
the immunoreactivity of the moAb. In this rat model, the in vivo biodistribution of 89Zr-Df-cG250 was
identical to that of 111In-DTPA-cG250. Immuno-PET of RCC is feasible with 89Zr-cG250, and relatively
small tumors could be visualized, even without a dedicated PET camera for small animals.




Whole-body positron emission tomography (PET)
offers some major advantages over whole-body
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scintigraphy with a gamma camera: (1) better 
detection of smaller lesions resulting from 
better spatial and temporal resolution, (2) more
accurate localization of lesions owing to 3-di-
mensional (3D) information, and (3) a more ac-
curate quantitative estimation of the uptake, al-
lowing for more reliable radiation dose estimates.
PET imaging with [18F]FDG is based on an 
enhanced glucose uptake by malignant cells.
Whereas, for a lot of malignancies, the role of
[18F]FDG-PET for the diagnosis, staging, and
more recently, assessing a response to treatment,
is evolving; for renal cell carcinoma (RCC), the
potential of [18F]FDG-PET is less well defined.1
RCC lesions in the abdomen may be difficult 
to detect, because of the physiological accumu-
lation of FDG in the urinary tract. Reports on
[18F]FDG-PET in RCC patients are scarce, and
cover relatively small numbers of patients.2–4
There is a renewed interest in radioimmuno-
scintigraphy (RIS) using positron emitters, also
designated as immuno-PET, for the visualization
of tumors. One of the reasons for this is the
rapidly expanding number of PET scanners.
However, the development of immuno-PET is
still in an early phase, mainly because the half-
life of most commonly used positron emitters
(11C, 18F, 15O, and 13N) is too short for use with
antibodies in vivo. This applies also for
positron emitters, such as 64Cu and 86Y, with
half-lifes (t1/2) of 12.7 and 14.7 hours, respec-
tively. Positron emitters like 89Zr and 124I with a
half-life of 78 and 100 hours better match the rel-
atively slow pharmacokinetics of radiolabeled
monoclonal antibodies (moAbs) (optimal uptake
in tumor lesions is usually reached after several
days for whole IgGs). PET imaging of tumors
with positron emitters labeled to moAbs could be
of particular interest not only for visualization
and staging, but also for dose planning in ra-
dioimmunotherapy (RIT).5 A method for the sta-
ble coupling of the positron emitter 89Zr to
moAbs was developed by Meijs et al.6 and fur-
ther improved by Verel et al.7 MoAbs could be
easily and stably radiolabeled with zirconium via
a desferal analogue that can be coupled to moAbs,
N-succinyldesferrioxamine B (N-sucDf). 89Zr-Df
labeled to chimeric (c) moAb U36, directed
against head and neck cancer, showed excellent
in vitro stability.7 In vivo, 89Zr after release from
the chelate may incorporate into the bone, as is
also observed for other metallic radionuclides,
such as 90Y and 177Lu.8–10 Therefore, stable la-
beling is crucial. High specific tumor accumula-
tion in HNX-OE tumors in nude mice was dem-
onstrated with 89Zr-Df-cU36. Small tumors
(19–154 mg) were clearly visualized with a pro-
totype animal PET scanner.7
In our group, we have ample experience with
RIS and RIT, using chimeric human/mouse moAb
G250 targeting RCC.11,12 The aim of this study
was to explore immuno-PET with 89Zr-Df-cG250.
The radiolabeling characteristics of 89Zr-Df-
cG250, the biodistribution, and its performance as
a PET imaging tracer were studied in nude rats
with subcutaneous (s.c.) RCC xenografts. In ad-
dition, in the same nude rat model, the in vivo
characteristics of 111In-labeled cG250 (RIS) and
[18F]FDG (FDG-PET) were studied and com-
pared to those of 89Zr-Df-cG250.
MATERIAL AND METHODS
Chimeric Monoclonal Antibody G250
The isolation and the immunohistochemical re-
activity of moAb G250 have been described else-
where.11,12 MoAb cG250 is reactive with the 
antigen G250 (Ka 5 4 3 109 M21), being the tu-
mor-associated isoenzyme carbonic anhydrase
isoenzyme IX (MN/CA IX).13 It is expressed on
the cell surface of nearly all clear cell RCCs, and
is absent on most normal tissues and other ma-
lignancies.11,12,14,15
Conjugation, Radiolabeling, and 
Quality Control
The conjugation of N-succinyldesferrioxamine B
(N-sucDf) to moAb cG250 was performed, as 
has been described previously.7 Briefly, desferal 
(Novartis Pharma AG, Bern, Switzerland) was suc-
cinylated (N-sucDf), temporarily filled with Fe31,
and coupled to cG250 via the tetrafluorophenol-N-
sucDf-ester. After the conjugation of Df to the
moAb, the removal of the Fe31 and the labeling of
the Df-conjugated moAb with 89Zr,16 the conjugate
was purified on a PD-10 column (Amersham Phar-
macia Biotech, Uppsala, Sweden), using 0.9%
NaCl1 5 mg/mL of gentisic acid, with a pH of
5.0, as the eluent. Df-cG250 (0.37 mg) was labeled
with 165 MBq of 89Zr during 30 minutes in 0.25
M HEPES buffer, with a pH of 7.3.
cG250 was conjugated with isothiocyanato-ben-
zyl-diethylenetriaminepentaacetic acid (SCN-Bz-
DTPA) (Macrocyclics, Richardson, TX) in a 0.1 M
NaHCO3 buffer, with a pH of 8.5, using a fifty-
fold (SCN-Bz-DTPA) molar excess, as described
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by Ruegg et al., with a minor modification (a con-
jugation period of 1 hour at room temperature).17
Unconjugated DTPA was removed from the moAb
preparation by extensive dialysis against 0.25 M of
ammonium acetate buffer, with a pH of 5.4. The
cG250-DTPA conjugate was labeled with 111InCl3
(Tyco Healthcare, Petten, The Netherlands) in 0.25
M of ammonium acetate buffer, with a pH of 5.4
(30 minutes at room temperature). The 111In-cG250
preparation was purified on a PD-10 column, us-
ing phosphate buffered saline (PBS), supplemented
with 0.5% of the bovine serum albumin (BSA) as
the eluent. The number of N-sucDf or DTPA li-
gands per cG250-molecule was determined as de-
scribed by Verel et al.7 and Hnatowich et al.,18 re-
spectively.
The radiochemical purity of the radiolabeled
cG250 preparations was determined by instant
thin layer chromatography (ITLC), using ITLC
silica gel strips (Gelman Sciences, Inc., Ann Ar-
bor, MI), and 0.1 M of citrate buffer (pH 6.0) for
111In-DTPA or 0.02 M of citrate buffer (pH 5.0)
for 89Zr-Df-cG250 as the mobile phase.
At the time of intravenous (i.v.) injection, the
immunoreactive fraction at infinite antigen ex-
cess of the radiolabeled cG250 preparations was
determined on freshly trypsinized SK-RC-52
RCC cells, essentially as described by Lindmo et
al., with minor modifications.12,19
To assess the stability of the 111In- and 89Zr-la-
beled preparations, both the 111In- and 89Zr-
labeled MoAb preparations were diluted in human
plasma at an activity concentration of 1.8
MBq/mL. A final concentration of 0.5 mM ethyl-
enediaminetetraacetic acid (EDTA) was added to
capture released radiometal, and the preparations
were incubated at 37°C. Plasma samples of both
89Zr-Df-cG250 and 111In-DTPA-cG250 were an-
alyzed at 0 and 4 hours and 1, 2, and 4 days of in-
cubation by fast protein liquid chromatography
(FPLC), using a Biosep Sec-S3000 gel filtration
column (Phenomenex, Torrace, CA). The column
was calibrated with IgG (Rf 5 11 minutes), trans-
ferrin (Rf 5 12 minutes), 111In (Rf 5 17 minutes),
and 111In-DTPA (Rf 5 17 minutes).
18F-Labeled Deoxyglucose
Clinical grade [18F]FDG was purchased from
Tyco Healthcare, Petten, The Netherlands.
Nude Rats Tumor Model
The RCC cell line SK-RC-52 was derived from
a mediastinal metastasis of a primary RCC, and
has been described elsewhere.20 SK-RC-52 cells
were cultured in a RPMI medium (Life Tech-
nologies, Breda, The Netherlands), supplemented
with 10% of fetal calf serum (FCS) and 100 mM
glutamine (Life Technologies, Breda, The
Netherlands) at 37°C in a humidified atmosphere
with 5% CO2. Cells were washed with saline,
trypsinized, washed in RPMI1 10% FCS, and
1 3 107 cells (volume 0.2 mL) were injected sub-
cutaneously (s.c.) into the right flank of 8–10
week-old RNU nude rats (Charles River Labora-
tories, Wilmington, MA). The biodistribution ex-
periments were initiated 14–20 days after the in-
oculation of tumor cells (mean tumor weight
0.126 0.04 g). All animal experiments were ap-
proved by the Animal Experiments Committee of
the University Medical Center at Nijmegen, and
were performed in accordance with their guide-
lines.
Imaging
After an i.v. injection of 4 MBq 111In-DTPA-
cG250 (n 5 6), rats were anesthetized with a
mixture of nitrous oxide/oxygen/isoflurane and
placed prone on the parallel-hole, medium-en-
ergy collimator of a gamma camera (Orbiter,
Siemens Medical Systems, Inc., Hoffman Es-
tates, IL). Images were recorded with a preset
count of 300,000 counts at 5 minutes and 24, 48,
and 72 hours postinjection (p.i.). The images
were digitally stored in a 2563 256 matrix.
After an i.v. injection of 20 MBq 89Zr-Df-
cG250 (n 5 8), rats were anesthetized and placed
prone in a PET scanner (ECAT EXACT, Siemens/
CTI, Knoxville, TN) (Radical and transaxial res-
olutions are 5.4 and 6.0 mm, respectively, at full
width at half maximum at the center of the field
of view). Emission images were recorded at 5
minutes (recording time (r.t.) 8 minutes), and 24
(r.t. 10 minutes), 48 (r.t. 12 minutes), and 72
hours p.i. (r.t. 16 minutes) in 3D mode. Each
emission scan was followed by a 5-minute trans-
mission scan with a 68Ge rod-source (2D mode).
The cG250 antibody protein dose was always be-
tween 50 and 100 mg/rat.
After an i.v. injection with 4 MBq [18F]FDG
(n 5 7), rats were placed prone in the PET scan-
ner and images were recorded at 1 hour p.i. (to-
tal r.t. 20 minutes in 3D mode). From the time of
the [18F]FDG injection until the completion of
the PET scan, the rats were sedated with the 
same mixture of nitrous oxide/oxygen/isoflurane.
All recorded PET images were iteratively re-
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constructed with ECAT software (version 7.2.1,
Siemens/CTI, Knoxville, TN), consisting of 2 it-
erations, with 16 subsets without recon filtering.
Biodistribution Experiments
At the end of each imaging experiment, at 2 hours
p.i. of [18F]FDG or 72 hours p.i. of 111In- and
89Zr-labeled cG250, the rats were killed with a
lethal dose of sodium pentobarbital. Blood sam-
ples, muscle, tumor, lung, spleen, kidney, liver,
and small intestine samples were collected. The
dissected tissues were weighed and counted in a
gamma counter (1480 Wizard 30, PerkinElmer
Life Sciences, Boston, MA). To correct for ra-
dioactive decay, injection standards were counted
simultaneously. The activity in the samples was
expressed as the percentage of injected dose per
gram of tissue (%ID/g).
Statistical Analysis
Statistical analysis was performed, using the non-
parametric (Kruskal-Wallis) repeated measures
one-way analysis of variance (ANOVA). Dif-
ferences were considered significant when p ,
0.05, two-sided. If p , 0.05, Dunn’s multicom-
parison procedure was performed, selecting only
relevant pairs for testing. All values are expressed
as the mean 6 standard deviation (s.d.).
RESULTS
Conjugation, Radiolabeling, and 
Quality Control
Approximately one N-sucDf moieties or two
SCN-Bz-DTPA were conjugated per cG250
IgG molecule. The specific activity of both
89Zr-Df-cG250 and 111In-DTPA-cG250 was 0.4
MBq/mg. At the time of i.v. injection, the ra-
diochemical purity of 89Zr-Df-cG250 and 111In-
cG250 was 97.4% and 98.5%, respectively. The
immunoreactivity at infinite antigen excess of
both preparations exceeded 95%. FPLC analy-
sis of the preparations after incubation in hu-
man plasma indicated that both radiolabeled
cG250 preparations exhibited high in vitro sta-
bility: During 4 days of incubation, less than
10% of the 89Zr and 111In radiolabel was re-
leased from the moAb.
Imaging
As shown in Figure 1, [18F]FDG did not accu-
mulate in the SK-RC-52 RCC tumors sufficiently
to visualize the tumors with [18F]FDG-PET. In
contrast, in rats injected with 89Zr-Df-cG250
from 24 hours p.i. onwards, the small tumors
were visualized with PET (Fig. 2). Images im-
proved with time, and at 72 hours p.i. all tumors
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Figure 1. PET anterior projection images of 4 nude rats with SK-RC-52 tumors induced at the right foreleg at 1 hour after an
i.v. injection of [18F]FDG. No uptake was observed in the tumors. Note the heart uptake in the rats (arrow). Variable uptake in
this organ is also found in humans.
were visualized (Fig. 2). The planar images of the
rats injected with 111In-DTPA-cG250 are shown
in Figure 3. From 24 hours onwards, tumors were
clearly visualized, and at later time points, im-
ages improved.
Biodistribution Experiments
The biodistribution of [18F]FDG at 2 hours p.i.,
and of 89Zr-Df-cG250 and 111In-DTPA-cG250 at
3 days p.i. is summarized in Figure 4. In accor-
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Figure 2. PET anterior projection images of 4 nude rats with SK-RC-52 tumors at the right shoulder at 24, 48, and 72 hours
after an i.v. injection of 89Zr-Df-cG250. Five (5) minutes after injection, tumors were not visualized (images not shown). At 24
hours postinjection (p.i.), three RCC tumors were visualized (rat #2–4), whereas, from 48 hours p.i. onwards, tumors were visu-
alized in all rats (arrows). One rat showed a remarkable uptake in the vicinity of the eyes, most likely the result of a local in-
flammatory response.
dance with the imaging results, no enhanced up-
take of [18F]FDG in the SK-RC-52 tumor could
be demonstrated, as tumor uptake (0.5 6 0.1
%ID/g) did not differ significantly from the up-
take in the muscle (0.4 6 0.2 %IDg), or various
other organs (Fig. 4).
In contrast, in the rats that received 89Zr- or
111In-labeled cG250, the uptake in the tumor was
higher than in any other tissue (5.06 2.4 %ID/g
and 4.96 2.9 %ID/g, respectively). Because the
activity in the blood was not significantly differ-
ent in the two groups of rats, tumor-to-blood ra-
tios were similar (3.1 for 89Zr-Df-cG250, and 2.9
for 111In-DTPA-cG250). Also, activity in other
normal tissues was not significantly different be-
tween the two radiolabeled cG250 groups.
DISCUSSION
This study showed that 89Zr-labeled moAb
cG250 can be used for immuno-PET of RCC 
tumors. Even without the use of a dedicated an-
imal PET camera, relatively small tumors of 
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Figure 3. Scintigraphic images of three rats with SK-RC-52 tumors induced at the right shoulder at 5 minutes, and 24, 48, and
72 hours after an i.v. injection of 111In-DTPA-cG250. From 24 hours p.i. onwards, the RCC tumors are visualized (arrow).
approximately 100 mg were visualized with 
89Zr-Df-cG250 from 24 hours p.i. onward. In
general, the maximum accretion of intact radio-
labeled moAbs in tumors is reached several days
after i.v. injection. In this study, the most opti-
mal images were acquired at 72 hours p.i. of 89Zr-
Df-cG250. Furthermore, our data showed that the
radioimmunoconjugate was stable in human
serum and that the immunoreactivity of radiola-
beled moAb cG250 was preserved.
We compared the imaging potential and bio-
distribution of 89Zr-Df-cG250 immuno-PET with
that of 111In-DTPA-cG250 RIS. As with 89Zr-Df-
cG250, the s.c. RCC xenografts were well visu-
alized with 111In-DTPA-cG250 from 24 hours p.i.
onwards, and the quality of the RCC tumor im-
age improved with time. The uptake of 89Zr-
Df-cG250 in the tumor was as high as that of
111In-DTPA-cG250, while the uptake of both 
radiolabels in normal tissues was similar. Re-
garding tumor visualization, the PET images of
89Zr-Df-cG250 were at least as informative as the
images obtained with 111In-DTPA-cG250. Obvi-
ously, the PET images of the rats are suboptimal,
because no small animal PET camera with a
gantry of a small diameter was available. In both
89Zr-Df-cG250 and 111In-DTPA-cG250 images,
a relatively high uptake was seen in the liver, the
spleen, and in the heart. In patients, frequent sites
of RCC metastases are the lungs (50%–60%) and
intraabdominal: the regional lymph nodes and
liver (30%–40%), the adrenal gland (20%) and
the contralateral kidney (10%).21 Potentially,
small metastases in the upper abdomen can be
better detected with 3D PET imaging than with
planar whole-body RIS, because with the former
technique, specific uptake in RCC lesions may
be better delineated from physiological uptake in
the surrounding tissues (liver and spleen). Also, 
potentially immuno-PET can accurately detect
small lesions in the lungs, because the resolution
of a PET system is higher than the resolution of
a gamma camera. The detection rate of pul-
monary lesions in RCC patients with 131I-cG250
RIS is disappointingly low.22
The uptake of [18F]FDG in the tumor was 
similar to that in the surrounding tissues and,
therefore, the RCC tumors were not visualized
with [18F]FDG. In humans, a variable uptake 
of [18F]FDG in RCC lesions has been re-
ported.2,22–24 Interestingly, in a direct compari-
son of RIS with 131I-cG250 and PET imaging
with [18F]FDG in patients with metastatic RCC,
70% of the RCC metastases were visualized with
[18F]FDG.22 This relatively low sensitivity of
[18F]FDG-PET suggests that at least a part of the
RCC lesions has a relatively low [18F]FDG up-
take, presumably reflecting a relatively low glu-
cose metabolism. In that study, the sensitivity of
131I-cG250 was even lower (30%). We have re-
cently shown that uptake of cG250 labeled with
the residualizing metallic radionuclides (e.g.,
111In, 88/90Y, and 177Lu) in RCC lesions is higher
than that of 131I-cG250.25,26 Therefore, with a
residualizing radionuclide, potentially higher ra-
diation doses can be guided to RCC lesions in
RIT with moAb cG250.25,26 The fact that, in this
study, the uptake of 89Zr-Df-cG250 in the tumor
was identical to that of 111In-DTPA-cG250 con-
firms that 89Zr should also be classified as a resid-
ualizing radionuclide. Thus, the combination of
3D PET imaging and the use of a metallic ra-
dionuclide labeled to cG250 (immuno-PET imag-
ing with 89Zr-Df-cG250) could improve the de-
tection rate of metastatic lesions in RCC patients.
In general, with immuno-PET presumably
smaller lesions can be visualized, and a more ex-
act localization of the metastases can be given as
a result of the improved spatial resolution of 
PET imaging over single photon imaging with a
gamma camera. Moreover, PET images can be
quantitatively analyzed more accurately than 
planar whole-body or single photon emission
computed tomography (SPECT) images, allow-
ing for a more accurate estimation of radiation-
absorbed doses in RIT treatment planning.27 As
has been demonstrated, 89Zr-Df-cU36 and 88Y-
p-SCN-Bz-DOTA-cU36 showed identical phar-
macokinetics and uptake in relevant organs, in-
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Figure 4. Biodistribution of [18F]FDG (n5 7), 89Zr-Df-
cG250 (n5 8), and 111In-DTPA-cG250 (n5 6) in nude rats
with subcutaneous (s.c.) SK-RC-52 RCC tumors at 2 hours
p.i. ([18F]FDG) or 72 hours p.i. (89Zr- and 111In-labeled
cG250).
dicating that 89Zr-labeled moAbs can be used to
estimate the radiation doses to relevant organs
following an injection of 90Y-labeled moAbs in
RIT.28
CONCLUSIONS
In summary, the cG250 antibody was stably la-
beled with the positron-emitter 89Zr. The label-
ing procedure did not affect the immunoreactiv-
ity of the antibody. In the nude rat RCC tumor
model, the uptake of 89Zr-Df-cG250 in the tumor
was identical to that of 111In-DTPA-cG250 and
higher than in all normal tissues tested. As a re-
sult, the relatively small tumors were visualized
with both 111In-DTPA-cG250 RIS and 89Zr-Df-
cG250 immuno-PET, even without the use of a
dedicated animal PET camera. Regarding the de-
lineation of uptake in surrounding tissues next to
the uptake in normal organs, such as the liver and
spleen, the 89Zr-Df-cG250 images were supe-
rior to the 111In-DTPA-cG250 images. 89Zr-Df-
cG250 PET imaging could improve the detection
of metastatic lesions in RCC patients. It can be
anticipated that, with immuno-PET, smaller le-
sions can be visualized and a more exact local-
ization of the metastases can be given as a result
of the improved spatial resolution of PET imag-
ing, as compared to single photon imaging. 
Finally, the more accurate estimates of radiation-
absorbed doses that can be obtained with im-
muno-PET, as compared to RIS with a gamma
camera, might be of value in the planning and
monitoring of RIT.
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